0001599901-24-000064.txt : 20240507 0001599901-24-000064.hdr.sgml : 20240507 20240507215258 ACCESSION NUMBER: 0001599901-24-000064 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240507 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boyce Sarah CENTRAL INDEX KEY: 0001629383 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39321 FILM NUMBER: 24924024 MAIL ADDRESS: STREET 1: C/O IONIS PHARMACEUTICALS, INC. STREET 2: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avidity Biosciences, Inc. CENTRAL INDEX KEY: 0001599901 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461336960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-401-7900 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Avidity Biosciences LLC DATE OF NAME CHANGE: 20161227 FORMER COMPANY: FORMER CONFORMED NAME: Avidity NanoMedicines LLC DATE OF NAME CHANGE: 20140211 4 1 wk-form4_1715133165.xml FORM 4 X0508 4 2024-05-07 0 0001599901 Avidity Biosciences, Inc. RNA 0001629383 Boyce Sarah C/O AVIDITY BIOSCIENCES, INC. 10578 SCIENCE CENTER DRIVE, SUITE 125 SAN DIEGO CA 92121 1 1 0 0 President and CEO 1 Common Stock 2024-05-07 4 M 0 28000 1.24 A 140117 D Common Stock 2024-05-07 4 S 0 28000 25.5375 D 112117 D Stock Option (Right to Buy) 1.24 2024-05-07 4 M 0 28000 0 D 2029-12-17 Common Stock 28000 845015 D The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.56. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact 2024-05-07